UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to ___________________ Commission File Number: 001-33035 11250 Waples Mill Road, South Tower 210, Fairfax, Virginia 22030 (Address of principal execu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Jet.AI Inc. (Exact Name of Registrant As Specified In Its Charter) Delaware 93-2971741 (State or other jurisdiction of (I.R.S. Employer incorporatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-40725 Jet.AI Inc. (Exact Name of Registrant As Specified In Its Charter) Delaware 93-2971741 (State or other jurisdictio ...

Financial Performance - The net loss for Q1 2025 was $15.7 million, compared to a net loss of $7.4 million in Q1 2024, representing an increase in loss of $8.2 million[112]. - The net loss for Q1 2025 was $15.7 million, with an accumulated deficit of $169.7 million as of March 31, 2025[118]. - Total operating expenses for Q1 2025 were $16.1 million, compared to $7.8 million in Q1 2024, reflecting an increase of $8.3 million[112]. - General and administrative expenses decreased to $3.4 million for Q1 2025 from $3.5 million in Q1 2024, primarily due to a $1.0 million reduction in legal and professional expenses[115]. - Net cash used in operating activities for Q1 2025 was $10.4 million, compared to $6.7 million in Q1 2024[127]. - The company has not generated any revenue from product sales or out-licensing and has never been profitable[118]. Cash Position - The company had approximately $45.9 million in cash and cash equivalents as of March 31, 2025[99]. - Cash and cash equivalents were approximately $45.9 million as of March 31, 2025, expected to fund operations for at least 12 months[122]. - The gross proceeds from the 2024 Private Placement were $53.0 million, with issuance costs of $3.4 million[120]. Research and Development - Research and development expenses increased to $12.7 million for Q1 2025, up from $4.4 million in Q1 2024, primarily due to an $8.9 million rise in manufacturing expenses for clinical trials[113]. - FB102, the current lead product candidate, is in Phase 1 clinical development, targeting autoimmune-related indications[123]. - A Phase 1 trial of FB102 demonstrated a good safety profile, with significant reductions in NK cell pharmacodynamic markers of over 70%[94]. - The company initiated a patient-based trial for celiac disease in Q3 2024, with top-line results expected in Q2 2025[94]. - The company expects to incur ongoing losses as it develops FB102, with future capital requirements difficult to forecast[123]. Market Potential - The global vitiligo treatment market is projected to reach $1.9 billion by 2026, indicating significant market potential for FB102[96]. - The global alopecia treatment market was valued at $2.7 billion in 2018 and is projected to reach $3.9 billion by 2026, with a CAGR of 4.6%[97]. Securities and Financing - Forte filed a new shelf registration statement for the issuance of up to $300 million in securities, effective April 2025[100]. - The company filed a shelf registration statement to register the issuance of up to $300 million in securities in March 2025[119]. - Net cash provided by investing activities for Q1 2025 was primarily due to proceeds from the redemption of U.S. treasury bills[130].

Exhibit 99.1 High Roller Reports Q1 2025 Results Las Vegas, Nevada, May 15, 2025 – High Roller Technologies ("High Roller" and the "Company") (NYSE: ROLR), operator of premium online casino brands High Roller and Fruta, today reported its financial results for the first quarter ended March 31, 2025. High Roller currently offers more than 5,300 games from over 90 game providers, representing one of the widest online casino game portfolios in the world, including video slots, blackjack, roulette, baccarat, cr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Exact Name of Registrant as Specified in its Charter) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc. Delaware 45-2437375 (State or other jurisdiction of incorporation or organi ...

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37716 Stratus Properties Inc. (Exact name of registrant as specified in its charter) Delaware 72-1211572 (State or other jurisd ...

Exhibit 99.1 LEGACY EDUCATION INC. ACHIEVES RECORD Q3 WITH 50% REVENUE GROWTH AND SURPASSES 3,000 ENROLLED STUDENTS Lancaster, California, May 15, 2025 (PR Newswire) — Legacy Education Inc. (NYSE American: LGCY), a leading provider of career-focused education and training, today announced financial and operating results for the third fiscal quarter ended March 31, 2025. Legacy Education Inc. will host a conference call to discuss third quarter financial results today, Thursday, May 15, 2025, at 4:30 p.m. Ea ...

Applied DNA Reports Second Quarter Fiscal 2025 Financial Results - Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues - - Intra-Quarter Investor Conference Call and Webcast Scheduled for June 3, 2025, at 4:30 PM ET - STONY BROOK, N.Y. – May 15, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its second quarter of fiscal 2025 e ...

EX-99.1 2 scwo_ex991.htm PRESS RELEASE EXHIBIT 99.1 374Water Reports First Quarter 2025 Financial Results DURHAM, NC – May 15, 2025 - 374Water Inc. (NASDAQ: SCWO) ("374Water") (the "Company"), a global leader in waste destruction technology for the municipal, federal, and industrial markets, today reported its financial and operational results for the first quarter ended March 31, 2025. "The first quarter of 2025 was focused on our robust, actionable backlog and pipeline and accelerating our proprietary Air ...